These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16648544)

  • 1. Antiparkinsonian prescription and extrapyramidal symptoms.
    Grover S; Kulhara P
    Br J Psychiatry; 2006 May; 188():492; author reply 492-3. PubMed ID: 16648544
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.
    Park S; Ross-Degnan D; Adams AS; Sabin J; Kanavos P; Soumerai SB
    Br J Psychiatry; 2005 Aug; 187():137-42. PubMed ID: 16055824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiparkinsonian agents and fluphenazine decanoate.
    Idzorek S
    Am J Psychiatry; 1976 Jan; 133(1):80-2. PubMed ID: 1247126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton].
    Kammerer T; Schweitzer-Bucher E; Jamet P; Royer M
    Ann Med Psychol (Paris); 1972 May; 1(5):688-96. PubMed ID: 5081112
    [No Abstract]   [Full Text] [Related]  

  • 5. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients.
    Wada Y; Yamaguchi N
    Neuropsychobiology; 1992; 25(3):149-52. PubMed ID: 1357583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses?
    Neu C; Dimascio A; Demirgian E
    Curr Ther Res Clin Exp; 1972 May; 14(5):246-51. PubMed ID: 4623975
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy.
    Lavin MR; Rifkin A
    J Clin Pharmacol; 1991 Aug; 31(8):769-77. PubMed ID: 1679063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gradual withdrawal of antiparkinson medication in chronic schizophrenics: any better than the abrupt?
    Manos N; Gkiouzepas J; Tzotzoras T; Tzanetoglou A
    J Nerv Ment Dis; 1981 Oct; 169(10):659-61. PubMed ID: 6116743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuing antiparkinson medication in chronic schizophrenics. At what cost to the patient?
    Manos N; Gkiouzepas J
    Acta Psychiatr Scand; 1981 Jan; 63(1):28-32. PubMed ID: 6112842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiparkinsonian agents and depot phenothiazine.
    Chien CP; Dimascio A; Cole JO
    Am J Psychiatry; 1974 Jan; 131(1):86-90. PubMed ID: 4808437
    [No Abstract]   [Full Text] [Related]  

  • 11. Antipsychotic prescribing patterns and the treatment of extrapyramidal symptoms in older people.
    Kalish SC; Bohn RL; Mogun H; Glynn RJ; Gurwitz JH; Avorn J
    J Am Geriatr Soc; 1995 Sep; 43(9):967-73. PubMed ID: 7657936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Withdrawal of antiparkinson drugs in long term neuroleptic treatment].
    Lerner J; Blum E; Fuchs I; Grinberg M
    Harefuah; 1978 Oct; 95(8):239-41. PubMed ID: 33879
    [No Abstract]   [Full Text] [Related]  

  • 13. Anticholinergics to treat antipsychotic-induced extrapyramidal symptoms: Time to avoid this practice.
    Koola MM
    Asian J Psychiatr; 2018 Jan; 31():100-101. PubMed ID: 29454175
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of novel antipsychotic drugs.
    Raleigh F
    Pharmacotherapy; 1996; 16(6 Pt 2):160S-165S; discussion 166S-168S. PubMed ID: 8948000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new synthetic antiparkinsonian drug, tropatepine hydrochloride in extrapyramidal syndromes induced by neuroleptics].
    Lambert A; dachary JM; Marie C; Oules J; Pagot R; Sales M; Vauterin C
    Encephale; 1976; 2(2):115-21. PubMed ID: 776591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon.
    Bermanzohn PC; Siris SG
    J Clin Psychiatry; 1994 Nov; 55(11):488-91. PubMed ID: 7989282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Algorithms for the treatment of acute side effects induced by neuroleptics.
    Kusumi I; Koyama T
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S19-22. PubMed ID: 10560893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients.
    McClelland HA; Blessed G; Bhate S; Ali N; Clarke PA
    Br J Psychiatry; 1974 Feb; 124(579):151-9. PubMed ID: 4596671
    [No Abstract]   [Full Text] [Related]  

  • 19. Dexetimide: an effective drug for the control of extrapyramidal symptoms induced by pipothiazine palmitate.
    Dom R; Van Lommel R; Baro F
    Acta Psychiatr Scand; 1973; 49(5):563-9. PubMed ID: 4148581
    [No Abstract]   [Full Text] [Related]  

  • 20. The association between cytochrome P450-2D6 genotype and prescription of antiparkinsonian drugs in hospitalized psychiatric patients using antipsychotics: a retrospective follow-up study.
    Mulder H; Wilmink FW; Belitser SV; Egberts AC
    J Clin Psychopharmacol; 2006 Apr; 26(2):212-5. PubMed ID: 16633157
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.